Home
Trials
Insights
Resources
Webinars
Groups
Courses
Library
Portfolio
Support Us
Newsletters
A phase III randomized controlled non-inferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) versus piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) - International Journal of Infectious Diseases
Welcome to the group! Connect with other members, get updates and share media.
Pioneer
